Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04203797 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
A Phase 4 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT04203797 is a Phase 4 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT04203797, a Phase 4 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. The secondary objectives of the study are: * To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma * To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma
Interventions
- DRUG Matching placebo
- DRUG dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2023-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04203797
The ClinicalTrials.gov registry entry for NCT04203797 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT04203797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04203797 about?
NCT04203797 is a clinical study titled "A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma". The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. The secondary objectives of the study are: * To demonstrate that dupilumab treatment increases physical activity of daily living in patients with mod...
What is the current status of trial NCT04203797?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-07-16. Estimated completion is 2023-07-15.
What interventions are being tested in trial NCT04203797?
The interventions under investigation include: Matching placebo (DRUG), dupilumab (DRUG).
Who is sponsoring clinical trial NCT04203797?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.